Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1 Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HIB210 in Healthy Volunteers

NCT05928585 is registered in ClinicalTrials.gov with HI-Bio, A Biogen Company as lead sponsor.

NCT NCT05928585
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05928585 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1 Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HIB210 in Healthy Volunteers
Lead sponsor
HI-Bio, A Biogen Company
Phase
Phase 1
Overall status
Completed
Start date
July 6, 2023
Completion date
June 10, 2024
Enrollment
30 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

autoimmunity, immune system diseases